FDA
-
-
-
-
-
-
-
Lumos Pharma (LUMO) Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Lumos Pharma (LUMO) Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
-
-
-
-
-
-
-
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
-
-
-
-
-
-
-
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
-
-
-
-
-
-
-
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
-
-
-
-
-
-
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
-
-
-
-
-
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

